Table 1.

Fasting and Postprandial Blood Glucose and A1C Responses to Pharmacologic Treatment in Patients With Type 2 Diabetes[2]

Drug	Decrease in FBG (mg/dL [mmol/L])	1-Hr PPG (Decrease From Baseline) (mg/dL [mmol/L])	Decrease in A1C (From Baseline) (%)
Sulfonylureas	40–60 (2.2–3.3)	–	1.0–2.0
Repaglinide/nateglinide	30.3 (1.7)	56.5 (3.1)	1.1
Metformin	53 (2.9)	–	1.4
Rosiglitazone (across dose range)	25–55 (1.4–3.0)	–	0.1–0.7
Pioglitazone	20–55 (1.1–3.0)	–	0.3–0.9
Alpha-glucosidase inhibitors	20–30 (1.1–1.7)	20–74 (1.1–4.1)	0.5–1.0

A1C = glycosylated hemoglobin A1C; FBG = fasting blood glucose; PPG = postprandial plasma glucose.